|
Bioject Medical Technologies wants to give the medical community a shot in the arm. Its Biojector 2000 jet injection system delivers injectable medication without a needle (and thus without needle-associated risks) by using a fine, high-pressure stream that goes through the skin; the injector is powered by CO2 disposable cartridges or tanks. The accompanying vial adapter device allows the Biojector system to be filled without a needle. The company also markets Vitajet, a spring-powered, needle-free self-injection device that has been cleared for administering injections of insulin and Merck Serono's human growth hormones. Investment firm Signet Healthcare Partners and affiliates own one-third of Bioject.
|
| | | Contact Information | |
Address: |
20245 SW 95th Ave.
Tualatin, OR 97062
| | Phone: | 503-692-8001 | | Fax: | 503-692-6698 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 6.50 M | | Revenue Growth (1 yr): | (-22.50%) | | Employees (2008): | 33 | | Employee Growth (1 yr): | (-8.30%) |
|
|
Key People
| | • |
Chairman:
David S. Tierney
| | • |
President and CEO:
Ralph Makar
| | • |
VP Finance and Administration:
Christine M. Farrell
|
|
|
